UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

The lancet oncology, 2013-05, Vol.14 (6), p.543-551

2013

Volltextzugriff (PDF)

Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-08, Vol.30 (22), p.2731-2738

2012

Volltextzugriff (PDF)

Differential Motion Between Mediastinal Lymph Nodes and Primary Tumor in Radically Irradiated Lung Cancer Patients

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (4), p.959-966

2014

Volltextzugriff (PDF)

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response

EBioMedicine, 2021-02, Vol.64, p.103160-103160, Article 103160

2021

Volltextzugriff (PDF)

Pre- and postoperative care for stage I–III NSCLC: which quality of care indicators are evidence-based?

Lung cancer (Amsterdam, Netherlands), 2016-11, Vol.101, p.120-128

2016

Volltextzugriff (PDF)

COUNTERPOINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? No

Chest, 2015-12, Vol.148 (6), p.1375-1379

2015

Volltextzugriff (PDF)

Rebuttal From Dr Li et al

Chest, 2015-12, Vol.148 (6), p.1380-1381

2015

Volltextzugriff (PDF)

Comments on Predictors of Clinical Use of Pleurodesis and/or Indwelling Pleural Catheter Therapy for Malignant Pleural Effusion

Chest, 2015-06, Vol.147 (6), p.e232-e232

2015

Volltextzugriff (PDF)

Tumour Treating Fields for mesothelioma

The lancet oncology, 2020-01, Vol.21 (1), p.e9-e9

2020

Volltextzugriff (PDF)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

Clinical pharmacology and therapeutics, 2021-02, Vol.109 (2), p.394-402

2021

Volltextzugriff (PDF)

Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer

Journal of clinical oncology, 2008-09, Vol.26 (25), p.4205-4207

2008

Volltextzugriff (PDF)

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study

The lancet oncology, 2023-11, Vol.24 (11), p.1219-1228

2023

Volltextzugriff (PDF)

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus

Virchows Archiv : an international journal of pathology, 2013-05, Vol.462 (5), p.547-556

2013

Volltextzugriff (PDF)

Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study

British journal of clinical pharmacology, 2023-02, Vol.89 (2), p.699-704

2023

Volltextzugriff (PDF)

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

Thorax, 2022-12, Vol.77 (12), p.1260-1267

2022

Volltextzugriff (PDF)

Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19

Lung cancer (Amsterdam, Netherlands), 2021-11, Vol.161, p.197-199

2021

Volltextzugriff (PDF)

Legal claims for malignant mesothelioma: Dealing with all cases

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80 (2), p.153-158

2013

Volltextzugriff (PDF)

The MUC5B promoter risk allele for idiopathic pulmonary fibrosis predisposes to asbestosis

The European respiratory journal, 2020-04, Vol.55 (4), p.1902361

2020

Volltextzugriff (PDF)

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe

Drug discovery today, 2023-08, Vol.28 (8), p.103620-103620, Article 103620

2023

Volltextzugriff (PDF)

Artificial intelligence-based diagnosis of asbestosis: analysis of a database with applicants for asbestosis state aid

European radiology, 2023-05, Vol.33 (5), p.3557-3565

2023

Volltextzugriff (PDF)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

Pharmaceutical research, 2022-04, Vol.39 (4), p.669-676

2022

Volltextzugriff (PDF)

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer

Drugs (New York, N.Y.), 2022, Vol.82 (1), p.15-32

2022

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(79)
Berichte
(1)

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(64)
Humans
(53)
Oncology
(31)
Female
(29)
Male
(28)
Aged
(24)
Adult
(23)
Middle Aged
(23)
Respiratory System
(20)
Treatment Outcome
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Tumors
(12)
Lung Neoplasms - Drug Therapy
(11)
Lung Neoplasms - Pathology
(11)
Retrospective Studies
(11)
Surgery
(11)
Aged, 80 And Over
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer

Differential Motion Between Mediastinal Lymph Nodes and Primary Tumor in Radically Irradiated Lung Cancer Patients

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response

Pre- and postoperative care for stage I–III NSCLC: which quality of care indicators are evidence-based?

COUNTERPOINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? No

Rebuttal From Dr Li et al

Comments on Predictors of Clinical Use of Pleurodesis and/or Indwelling Pleural Catheter Therapy for Malignant Pleural Effusion

Tumour Treating Fields for mesothelioma

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus

Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof‐of‐concept study

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19

Legal claims for malignant mesothelioma: Dealing with all cases

The MUC5B promoter risk allele for idiopathic pulmonary fibrosis predisposes to asbestosis

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe

Artificial intelligence-based diagnosis of asbestosis: analysis of a database with applicants for asbestosis state aid

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer

Suchergebnisse filtern